Boehringer Ingelheim disclosed Phase 3 results for survodutide, reporting 16.6% mean weight loss after about a year of treatment, using a dual-agonist approach that targets GLP-1 and glucagon pathways. The company positioned the program as aiming to improve cardiometabolic outcomes beyond existing GLP-1-based therapies, even as headline efficacy trails the strongest marketed comparators. The readout leaves unanswered questions on how patients will translate into longer-term outcomes, including durability of weight loss and cardiometabolic risk reduction. Boehringer’s next steps will likely focus on clarifying the degree of benefit across endpoints that regulators and payers weigh when evaluating obesity and cardiometabolic risk reduction therapies. For the broader field, the update underscores how the obesity market continues to shift from weight-loss magnitude alone toward cardiometabolic utility and differentiated dosing or safety profiles.